Literature DB >> 25037256

Dermatologic adverse events to chemotherapeutic agents, part 1: cytotoxics, epidermal growth factor receptors, multikinase inhibitors, and proteasome inhibitors.

Rachel L Kyllo, Milan J Anadkat1.   

Abstract

Dermatologic toxicities have profound effects on patients receiving chemotherapy for cancer treatment. Cytotoxic chemotherapies are associated with a number of nonspecific dermatologic adverse events including alopecia, mucositis, and onychodystrophy. Targeted therapies including epidermal growth factor inhibitors, multikinase inhibitors, and proteasome inhibitors are associated with different skin reactions that are class-specific. In Part 1 of this review, we examine the presentations of the most common dermatologic adverse events associated with the above drugs and discuss the strategies used for their prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25037256     DOI: 10.12788/j.sder.0060

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  6 in total

Review 1.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

2.  Amino Acids May Have Protective Effects on Salivary Glands of 5-FU-administered Mice.

Authors:  Rieko Fujiwara; Koji Harada; Tarannum Ferdous; Katsuaki Mishima
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

3.  An elemental diet protects mouse salivary glands from 5-fluorouracil-induced atrophy.

Authors:  Koji Harada; Tarannum Ferdous; Rieko Fujiwara; Kenji Watanabe; Yoichi Mizukami; Katsuaki Mishima
Journal:  Oncol Lett       Date:  2022-04-14       Impact factor: 3.111

Review 4.  Management of Dermatologic Complications of Lung Cancer Therapies.

Authors:  Silvina B Pugliese; Joel W Neal; Bernice Y Kwong
Journal:  Curr Treat Options Oncol       Date:  2015-10

5.  Elemental Diet Accelerates the Recovery From Oral Mucositis and Dermatitis Induced by 5-Fluorouracil Through the Induction of Fibroblast Growth Factor 2.

Authors:  Koji Harada; Tarannum Ferdous; Hiroaki Kobayashi; Yoshiya Ueyama
Journal:  Integr Cancer Ther       Date:  2017-07-26       Impact factor: 3.279

6.  Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.

Authors:  J Wu; D Liu; M Offin; B T Li; M E Lacouture; C Lezcano; J M Torrisi; S Brownstein; D M Hyman; M M Gounder; W Abida; A Drilon; J J Harding; R J Sullivan; F Janku; D Welsch; M Varterasian; A Groover
Journal:  Invest New Drugs       Date:  2021-01-03       Impact factor: 3.651

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.